PLUR
HEALTHCAREPluri Inc
Live · NASDAQ · May 9, Close
What's Moving PLUR Today?
No stock-specific AI insight has been generated for PLUR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.30
Fundamentals
Trading
PLUR News
19 articles- EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes DrugYahoo Finance·May 1, 2026
- Plurilock Announces Payment of Debenture InterestYahoo Finance·Mar 31, 2026
- Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementYahoo Finance·Mar 26, 2026
- Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentYahoo Finance·Feb 18, 2026
- Pluri: Fiscal Q2 Earnings SnapshotYahoo Finance·Feb 12, 2026
- Pluri showcases cell expansion platform as Resbiomed program advancesYahoo Finance·Feb 9, 2026
- Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich BiomaterialsYahoo Finance·Jan 22, 2026
- Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing AchievedYahoo Finance·Dec 22, 2025
- A US$3.4m Market Cap Boost Pleasing ToPluri InsidersYahoo Finance·Dec 19, 2025
- Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional InvestmentYahoo Finance·Dec 9, 2025
- Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the YearYahoo Finance·Nov 13, 2025
- Pluri: Fiscal Q1 Earnings SnapshotYahoo Finance·Nov 12, 2025
- Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative SkincareYahoo Finance·Nov 11, 2025
- Leading Global Players Back and Fund Pluri’s Cell-Based Food and Agriculture CollaborationsYahoo Finance·Nov 10, 2025
- Plurilock Announces Insider Share PurchasesYahoo Finance·Oct 27, 2025
- Pluri Subsidiary Coffeesai Partners with Mexico’s INCAFECH to Advance Cell-Based Coffee ManufacturingYahoo Finance·Oct 24, 2025
- Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in MexicoYahoo Finance·Oct 8, 2025
- Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market ExpansionYahoo Finance·May 15, 2025
- Pluri: Fiscal Q3 Earnings SnapshotYahoo Finance·May 13, 2025
All 19 articles loaded
Price Data
52-Week Range
$3.30
Fundamentals
Trading
About Pluri Inc
Pluri Inc. is an innovative biotechnology company specializing in regenerative medicine and immunotherapy, focused on developing advanced cell-based therapies for oncology and degenerative diseases. Utilizing its proprietary technology platform, Pluri aims to improve patient outcomes and drive growth through a promising pipeline of therapeutics and strategic collaborations with industry partners. By harnessing the potential of human cells, the company is positioning itself as a key player in the biotechnology sector, committed to delivering transformative solutions that address critical unmet medical needs in the evolving healthcare landscape.